Sandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CAO Sandra Calvin sold 54,244 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now owns 54,410 shares of the company's stock, valued at $1,360,250. The trade was a 49.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sandra Calvin also recently made the following trade(s):

• On Monday, February 3rd, Sandra Calvin sold 3,348 shares of Travere Therapeutics stock. The shares were sold at an average price of $20.12, for a total value of $67,361.76.
• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.94, for a total value of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Stock Down 3.4 %

TVTX traded down $0.81 during trading on Friday, reaching $22.91. The company's stock had a trading volume of 1,466,790 shares, compared to its average volume of 1,303,585. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $25.29. The company's fifty day moving average price is $19.22 and its 200-day moving average price is $16.14. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TVTX. Cantor Fitzgerald began coverage on Travere Therapeutics in a research note on Friday, January 10th. They issued an "overweight" rating on the stock. Wells Fargo & Company upgraded Travere Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $9.00 to $27.00 in a research note on Monday, October 21st. HC Wainwright raised their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a research note on Wednesday, January 15th. Scotiabank raised their price target on Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a research note on Wednesday. Finally, Barclays raised their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Travere Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.77.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC lifted its position in shares of Travere Therapeutics by 859.8% during the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock valued at $41,000 after acquiring an additional 2,115 shares during the period. R Squared Ltd acquired a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $53,000. CWM LLC raised its position in shares of Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company's stock worth $70,000 after purchasing an additional 3,065 shares during the last quarter. Quarry LP acquired a new position in Travere Therapeutics in the 3rd quarter valued at $105,000. Finally, Ameritas Investment Partners Inc. raised its holdings in Travere Therapeutics by 9.2% in the 4th quarter. Ameritas Investment Partners Inc. now owns 7,905 shares of the company's stock valued at $138,000 after acquiring an additional 667 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.